Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.

EMBO molecular medicine - 9 Apr 2021

Marrocco Ilaria, Romaniello Donatella, Vaknin Itay, Drago-Garcia Diana, Oren Roni, Uribe Mary Luz, Belugali Nataraj Nishanth, Ghosh Soma, Eilam Raya, Salame Tomer-Meir, Lindzen Moshit, Yarden Yosef

Abstract excerpt

Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti-cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop resistance to the first-, second-, and third-generation drugs. To explore alternatives to such whack-a-mole strategies, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Organic Chemicals

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 33660397
DOI: 10.15252/emmm.202013144
PMCID: PMC8033519

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.PMID 33660397Read ↗

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read ↗

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.Semantic proximity Read ↗

Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?Semantic proximity Read ↗

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance.Semantic proximity Read ↗

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.Semantic proximity Read ↗

Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.Semantic proximity Read ↗

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.Semantic proximity Read ↗

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenograftsSemantic proximity Read ↗

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read ↗

Correlated Drug Action as a Baseline Model for Combination Therapy in Patient Cohorts and Cell CulturesSemantic proximity Read ↗

A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.